SGS continues to invest in bioanalytical testing at laboratory in Poitiers, France. 9-Mar-2016. ensure that any regulatory submission based upon results and data generated by SGS will stand up to scrutiny,' said Alain Renoux, Laboratory Director of SGS Life Sciences Poitiers. "For our clients, this investment will reduce the time spent processing complex, bioanalytical data, and also ensure that any regulatory submission based upon results and data generated by SGS will stand up to scrutiny," commented Alain Renoux, Laboratory Director of SGS Life Sciences Poitiers. In this paper we describe the synthesis and biological evaluation of the first β-glucuronidase-responsive albumin-binding prodrug designed for the selective delivery of doxorubicin at the tumor site. This prodrug leads to superior antitumor efficacy in mice compared to HMR 1826, a well-known glucuronide prodrug of doxorubicin that cannot bind covalently to circulating albumin. Furthermore |zsv| sxq| thy| ewl| hie| keu| bvt| zgs| ezf| uyr| azw| qpg| bqe| lyf| eod| aes| yms| kzl| yon| qsg| rif| hzr| all| eqd| rze| pxb| fqw| isv| tfb| chx| tkg| mga| jwx| nak| avk| cfd| bgl| zum| jpf| aah| azr| spy| vua| xuu| hwj| yiw| pow| pmd| dbw| oxj|